【摘要】 目的探讨Ephrin A型受体4(EPHA4)基因多态性与卵巢癌紫杉醇化疗疗效和毒性反应的相关性。方法前瞻性队列研究2011年6月至2014年3月沧州市中心医院妇产科收治的接受紫杉醇治疗的Ⅳ期卵巢癌病人129例,并通过基因测序法对纳入患者外周血细胞基因组中EPHA4基因rs17348202、XKR基因rs4737264多态性进行检测分型,结合临床资料,分析其与紫杉醇的毒性反应及疗效的相关性。结果 EPHA4基因rs17348202检测到CC、CT、TT 3种基因型,在队列中频率分别为18.6%、32.6%和48.8%。化疗安全性方面EPHA4基因rs17348202 TT型(OR=2.77,95%CI 1.11~8.39,χ2=4.02,P=0.04)为严重毒性反应的独立预测因素;有效性方面,EPHA4基因与化疗疗效显著相关(OR=2.40,95%CI 1.26~22.11,χ2=4.84,P=0.03)。而XKR基因rs4737264多态性与化疗安全性和有效性无相关性(P>0.05)。结论 EPHA4基因rs17348202多态性与卵巢癌紫杉醇化疗安全性和有效性显著相关,XKR基因rs4737264与之无相关性。更多还原

【Abstract】 Objective To evaluate the association of ephrin type A receptor 4 gene polymorphisms and efficacy/safety profile of paclitaxel therapy.Methods A prospective cohort study was conducted on 129 patients receiving paclitaxel treatment in Cangzhou Central Hospital.The clinical and pathological data were retrieved, and polymorphic genotype was detected through gene sequencing.These data was analysed concerning sereve toxicity and objective response.Results CC/CT/TT genotypes was detected in rs17348202 loci, the frequencies in total being 18.6%,32.6% and 48.8%.TT type was more suspicious to severe toxicity(OR=2.77,95% CI 1.11~8.39,P=0.04), while more responsive(OR=2.40, 95% CI1.26~22.11,P=0.03).XRK gene rs4737264 was not significantly associated with chemotherapy safety and response(P>0.05).Conclusion The EPHA4 gene polymorphism rs17348202 is a significantly marker for better response but with more toxicity, while XRK gene rs 4737264 is not associated with chemotherapy.更多还原